Braeburn Announces Publication of a Post Hoc Analysis of Data from Patients Using Fentanyl Treated with BRIXADI in a Phase 3 Efficacy and Safety Study
Estimated read time 1 min read
Posted in Health Trends Health Trends - New Zealand

Braeburn Announces Publication of a Post Hoc Analysis of Data from Patients Using Fentanyl Treated with BRIXADI in a Phase 3 Efficacy and Safety Study

admin

PLYMOUTH MEETING, Pa., June 25, 2024 /PRNewswire/ — Braeburn Inc. announces the publication of a post hoc analysis in the Journal of the American Medical Association (JAMA) Network Open. The analysis evaluated data in patients with evidence of fentanyl use from the Phase 3 Clinical Efficacy…

[ad_2]

Source link

You May Also Like

More From Author

“No evidence” new COVID variant LB.1 causes more severe disease, CDC says

“No evidence” new COVID variant LB.1 causes more severe disease, CDC says

The dermatologists’ 10-point skin cancer prevention guide

The dermatologists’ 10-point skin cancer prevention guide

Leave a Reply

Your email address will not be published. Required fields are marked *